Catalyst Pharmaceutical Partners, Inc. Release: Scientific Paper Regarding CPP-115 for the Treatment of Cocaine Addiction Accepted for Publication in the Journal of Medicinal Chemistry

CORAL GABLES, Fla., Dec. 15, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Company) today announced that a scientific paper on CPP-115 describing preclinical data supporting its use as a treatment for cocaine addiction, its pharmacological target specificity, and its visual safety was accepted for publication in the Journal of Medicinal Chemistry (JMC). The paper, entitled "(1S,3S)-3-Amino-4-difluoromethylenyl-1-cyclopentanoic Acid (CPP-115), a Potent y-Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Cocaine Addiction" by Yue Pan, Madina R. Gerasimov, Trine Kvist, Petrine Wellendorph, Karsten K. Madsen, Elena Pera, Hyunbeom Lee, Arne Schousboe, Mary Chebib, Hans Brauner-Osborne, Cheryl M. Craft, Jonathan D. Brodie, Wynne K. Schiffer, Stephen L. Dewey, Stephen R. Miller, and Richard B. Silverman, was recently posted in JMC's web edition.